February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|The Day the HIV Treatment Pendulum Stopped Swinging|
|This Week in HIV Research: Major HIV Transmission Results; Case of HIV Remission; Gene Therapy; and More|
|Leading HIV Expert Live-Blogs From IAS 2015|
|HIV Treatment at High CD4 Counts Protects Against Both AIDS and Non-AIDS Events in the START Study: Overall and in Subgroup Analyses|
|HPTN 052: No Partner Infections With Viral Suppression|
|The Vancouver Consensus: A New Declaration Against HIV|